European Union - English - EMA (European Medicines Agency)

bayer ag - larotrectinib sulfate - abdominal neoplasms - antineoplastic agents - vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have no satisfactory treatment options.

Israel - English - Ministry of Health

bayer israel ltd - larotrectinib as sulfate - capsules - larotrectinib as sulfate 100 mg - larotrectinib - vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a neurotrophic tyrosine receptor kinase (ntrk) gene fusion:• who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and• who have no satisfactory treatment options

Israel - English - Ministry of Health

bayer israel ltd - larotrectinib as sulfate - solution (oral) - larotrectinib as sulfate 20 mg/ml - larotrectinib - vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,• who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and• who have no satisfactory treatment options

Israel - English - Ministry of Health

bayer israel ltd - larotrectinib as sulfate - capsules - larotrectinib as sulfate 25 mg - larotrectinib - vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a neurotrophic tyrosine receptor kinase (ntrk) gene fusion:• who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and• who have no satisfactory treatment options

Canada - English - Health Canada

bayer inc - larotrectinib (larotrectinib sulfate) - capsule - 25mg - larotrectinib (larotrectinib sulfate) 25mg - antineoplastic agents

Canada - English - Health Canada

bayer inc - larotrectinib (larotrectinib sulfate) - capsule - 100mg - larotrectinib (larotrectinib sulfate) 100mg - antineoplastic agents

Canada - English - Health Canada

bayer inc - larotrectinib (larotrectinib sulfate) - solution - 20mg - larotrectinib (larotrectinib sulfate) 20mg - antineoplastic agents